A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

NCT07190248 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

675

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: Calderasib
BIOLOGICAL: Pembrolizumab (+) Berahyaluronidase alfa
DRUG: Pemetrexed
DRUG: Cisplatin
DRUG: Carboplatin

Sponsor

Merck Sharp & Dohme LLC